Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis

Purpose High levels of tumor-infiltrating lymphocytes (TILs) are associated with better outcomes in early breast cancer and higher pathological response rates to neoadjuvant chemotherapy especially in the triple-negative (TNBC) and HER2+ subtypes. However, the dynamic changes in TILs levels after neoadjuvant treatment (NAT) are less studied. This systematic review and meta-analysis aimed to investigate the patterns and role of TILs dynamics change in early breast cancer patients receiving NAT. Methods Medline, Embase, Web of Science Core Collection and PubMed Central databases were searched for eligible studies. Data were extracted independently by two researchers and discordances were resolved by a third. Pooled TILs rates pre- & post-treatment (overall and per subtype), pooled rates of ΔTILs and direction of change after NAT as well as correlation of ΔTILs with survival outcomes were generated in the outcome analysis. Results Of 2116 identified entries, 34 studies fulfilled the criteria and provided adequate data for the outcomes of interest. A decreased level of TILs was observed after NAT in paired samples across all subtypes. The effect of NAT on TILs was most prominent in TNBC subtype with a substantial change, either increase or decrease, in 79.3% (95% CI 61.7-92.6%) of the patients as well as in HER2+ disease (14.4% increased vs 46.2% decreased). An increase in ΔTILs in TNBC was associated with better disease-free/relapse-free survival in pooled analysis (univariate HR = 0.59, 95% CI: 0.37–0.95, p = 0.03). Conclusion This meta-analysis illustrates the TILs dynamics during NAT for breast cancer and indicates prognostic implications of ΔTILs in TNBC. The potential clinical utility of the longitudinal assessment of TILs during neoadjuvant therapy warrants further validation.

[1]  S. Loi,et al.  Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Hortobagyi,et al.  21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. , 2021, The New England journal of medicine.

[3]  F. Dalenc,et al.  Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study , 2021, Breast cancer research : BCR.

[4]  B. Hennessy,et al.  The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer , 2021, Breast Cancer Research and Treatment.

[5]  P. Nuciforo,et al.  Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer , 2021, npj Precision Oncology.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  A. Vincent-Salomon,et al.  PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy , 2021, Cancers.

[8]  M. Abdelhamid,et al.  Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage TNBC treated with neoadjuvant chemotherapy. , 2020, Annals of diagnostic pathology.

[9]  N. Radosevic-Robin,et al.  PERCEPTION Trial protocol , 2020, Medicine.

[10]  J. Bienkowska,et al.  Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome , 2020, Nature Communications.

[11]  J. Bergh,et al.  PD-1 protein and gene expression as prognostic factors in early breast cancer , 2020, ESMO Open.

[12]  F. Reyal,et al.  Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy , 2020, medRxiv.

[13]  Jennifer L. Caswell-Jin,et al.  Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07) , 2020, Nature Communications.

[14]  M. Espié,et al.  Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC , 2020, Cancers.

[15]  S. Mallal,et al.  Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer , 2020, Clinical Cancer Research.

[16]  P. Fasching,et al.  Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  G. Gong,et al.  Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer , 2020, AntiCancer Research.

[18]  Emmanouil G. Sifakis,et al.  Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease , 2020, Molecular oncology.

[19]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[20]  X. Nie,et al.  Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS , 2020, Frontiers in Oncology.

[21]  Wenbin Zhou,et al.  Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy , 2019, Cancer management and research.

[22]  F. D. De Braud,et al.  Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy , 2019, Cancers.

[23]  A. Vincent-Salomon,et al.  Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy , 2019, Clinical Cancer Research.

[24]  C. Criscitiello,et al.  Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. , 2019, European journal of cancer.

[25]  K. Weber,et al.  A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Z. Szallasi,et al.  Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer , 2019, Acta oncologica.

[27]  J. Bergh,et al.  Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data , 2019, Clinical Cancer Research.

[28]  M. Kurosumi,et al.  Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer , 2019, Scientific Reports.

[29]  S Michiels,et al.  Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Heikki Joensuu,et al.  Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Lee,et al.  A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients , 2018, Breast Cancer Research and Treatment.

[32]  R. Emerson,et al.  Early Stage HER2‐Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab‐ or Pertuzumab‐Based Regimens Have an Immunosuppressive Phenotype , 2018, Clinical breast cancer.

[33]  S. Tomita,et al.  Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy , 2018, ESMO Open.

[34]  Jonas Bergh,et al.  Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer , 2018, Oncoimmunology.

[35]  T. Doman,et al.  Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms , 2018, Clinical Research (Excluding Clinical Trials).

[36]  Z. Szallasi,et al.  Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients , 2018, Journal of Cancer Research and Clinical Oncology.

[37]  G. Hortobagyi,et al.  Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial , 2018, Molecular Cancer Therapeutics.

[38]  S. Hirota,et al.  Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers , 2018, Breast Cancer Research and Treatment.

[39]  M. Fernö,et al.  Immune gene expression and response to chemotherapy in advanced breast cancer , 2018, British Journal of Cancer.

[40]  Carsten Denkert,et al.  Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). , 2017, European journal of cancer.

[41]  A. Vincent-Salomon,et al.  Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  Carsten Denkert,et al.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe , 2017, Advances in anatomic pathology.

[43]  L. Pusztai,et al.  Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance , 2017, Breast Cancer Research.

[44]  H. Gómez,et al.  Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy , 2016, World journal of clinical oncology.

[45]  D. Generali,et al.  Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  C. Verma,et al.  Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer , 2016, Journal of immunology research.

[47]  Sung-Bae Kim,et al.  Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential , 2016, Cancer Chemotherapy and Pharmacology.

[48]  A. Hida,et al.  Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies , 2016, Breast Cancer Research and Treatment.

[49]  Mike J. Irwin,et al.  Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer , 2016, Breast Cancer Research.

[50]  C. Sotiriou,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  G. Ball,et al.  HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer , 2014, British Journal of Cancer.

[54]  M. Mathieu,et al.  Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[57]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[58]  P. V. van Diest,et al.  Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. , 1997, American journal of clinical pathology.

[59]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[60]  K. Arihiro,et al.  Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[61]  P. Nuciforo,et al.  A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[63]  C. Sotiriou,et al.  A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012 .

[65]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  L. Zitvogel,et al.  Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.